Shares of Elicio Therapeutics, Inc. (ELTX) tumbled 72% on Monday morning after the company reported that its Phase 2 AMPLIFY-7P study of ELI-002 7P in pancreatic cancer failed to meet its primary endpoint.
The stock is currently trading at $4.06, down $10.79 or 72.66%, on the Nasdaq. It opened at $4.79 after closing the previous session at $14.85. The stock has traded between $3.75 and $16.00 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.